A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

ACUTE LYMPHOBLASTIC LEUKEMIA

Interventions

DRUG: Inotuzumab ozogamicin
DRUG: ALLR3

Sponsor

Pfizer